Interní Med. 2016; 18(5): 222-225 | DOI: 10.36290/int.2016.051

Antithrombotic therapy of thromboembolic disease

doc. MUDr. Ondřej Ludka, Ph.D.

Interní kardiologická klinika FN Brno, Lékařská fakulta MU, Mezinárodní centrum klinického výzkumu

FN u sv. Anny v Brně, Brno

Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). This is a relatively common cardiovascular disease with acute risk of death and possible long-term consequences, which affects approximately 2–5% of the population. Patients with PE are at risk up to 20% mortality rate and long-term consequences of VTE are also negligible. Post-thrombotic syndrome (PTS) occurs in up to 40% of patients and chronic thromboembolic pulmonary hypertension (CTPH) in 2–4%. The goal of treatment is to prevent progression, dislocation of thrombus, achieving maximum recanalization and prevention of relapse for which we used antithrombotic treatment (anticoagulation or thrombolytic therapy), rarely because a contraindication, we use surgical or endovascular treatment, or inferior vena cava filter implantation as the prevention of pulmonary embolism. Since the antithrombotic treatment entails the risk of bleeding complications, it is essential determining optimal treatment strategies. In the treatment of PE, we follow 2014 recommendations of the European Society of Cardiology (ESC). American College of Chest Physicians (ACCP), however this year, published in the Chest 10th Edition of the Antithrombotic Guideline, which brings some key recommendations for clinical practice.

Keywords: venous thromboembolic disease, deep vein thrombosis, pulmonary embolism, antithrombotic therapy

Published: December 1, 2016  Show citation